Abstract & Poster Requirements
Below you will find all the information about submitting your abstract for Mosa Conference 2018 on 19th & 20st June 2018.
Please notice that these requirements are for external students only. In other words, these requirements are only applicable if Mosa Conference is not part of your curriculum! Internal students (A-KO phase 1, A-KO phase 4 and 2nd year BMS UM and 2nd year BMS UHasselt) should contact their course coordinator for their study specific requirements or go to http://www.mosa-conference.nl/participation/abstract-requirements-internal-students/.
- 2018 – Extern Poster Requirements for MOSA conference
- 2018 – Extern Abstract Requirements for MOSA conference
Good luck on writing your abstract!
- Language: The abstract should be written in the English language
- Word limit: The limit of the abstract is 350 words. Title and author are not included. Characters that are not in isonorm 8859-1 cannot be used. This means: α, β or other Greek characters need to be spelled out (“alpha” and “beta”).
- File format: Preferably a Microsoft Word file (.doc or .docx). PDF files (.pdf) are also accepted, as long as the content is copyable (not secured).
- Format and point size: Arial, size
- Page Layout Guideline for A4: (21 cm x 29,7 cm) paper size. Page Layout should be as follows: Top – 3 cm, Bottom – 3 cm, Left – 3 cm, Right – 3 cm. This is important to ensure no text is lost when printing your
- Tables and figures: these can be added in addition to the abstract itself. The organisation of Mosa Conference cannot guarantee that tables and figures will be placed in the book of abstracts.
- Refer to your university in English, example: ‘Maastricht University’.
- Mention your co-authors.
Scientific abstracts should contain the following paragraphs:
In this paragraph you should describe the current state of scientific progress regarding your field. It should also contain the aim of your research and why it is important.
- Materials & methods:
In this paragraph, the used materials and methods should be described. Give a short summary of your population (humans, animals), the materials that have been used (equipment, chemicals, etc.), how you acquired your data (status, interviews, etc.) and how these have been analyzed statistically.
Next, you describe the results you have found. Make sure you do not reveal your conclusions yet. A small table or graphic is also possible; you can upload this later.
- Discussion & conclusions:
In this paragraph, you present the conclusions and outcomes from the interpretation of your results. You can also describe the limitations of your study, implications for future studies in this field and the consequences for others.
All abstracts need to be written in correct English with a maximum of 350 words (including spaces and interpunctions).
Important notice: Received abstracts that do not meet the submission requirements as described above, will not be published in the abstract book.
Example of an abstract, submitted in 2015 to Mosa Conference:
Multiple myeloma (MM) is a plasma cell disorder, characterized by an accumulation of malignant plasma cells in the bone marrow (BM). Despite the discovery of novel drugs, MM is still an incurable disease. The anaphase-promoting complex (APC) is an E3 ligase and contributes to cell cycle by ubiquitylation of cell cycle proteins such as securin and cyclin B and initiating anaphase. Genetic changes affecting APC and its regulator, the spindle assembly checkpoint are described in MM patients and are associated with chromosomal instability and aneuploidy. The purpose of this study is to examine APC as a possible new target in MM.
Material and methods
The APC inhibitor proTAME (pT) was tested on human MM cell lines (HMCL) LP1 and RPMI, MM patient cells and stromal cells. Cells in metaphase were morphologically counted on May-Grünwald Giemsa stained cytospins using a light microscope. Viability and apoptosis was determined by respectively the CellTiterGlo assay (Promega) and Annexin V/7AAD flow cytometry staining. Expression of apoptotic and cell cycle proteins was determined by western blot. Statistical analysis was performed by the Mann-Whitney t-test.
HMCL were treated with pT and mitosis was analysed by morphology. PT treatment induced a clear metaphase arrest that was accompanied by an accumulation of cyclin B which is consistent with APC inhibition. A prolonged metaphase can lead to cell death; therefore we measured viability and apoptosis. We observed a significant
dosedependent decrease in viability and increase in apoptosis when HMCL and purified patient MM cells were treated with pT. In contrast, no effect on viability could be observed on other cell types from the BM micro-environment. PT had similar effects on MM cells when growth factors (IL-6 or IGF-1) or BM stromal cells were added to the MM cells, indicating that the BM micro-environment cannot abrogate the action of pT. We further analysed the apoptosis mechanisms by western blot and could clearly detect an increased cleavage of caspase 3, 8, 9 and PARP in MM cells treated with pT.
We can conclude that pT induces a prolonged metaphase in HMCL, resulting in reduced viability and induction of apoptosis that is accompanied by PARP cleavage and caspase 3, 8 and 9 activation. These findings suggest that the APC complex may be a promising target in MM.